Wesfarmers Limited (WF3) News

Greatland Gold PLC managing director Shaun Day talked with Proactive about the company’s updated ore reserve for the Telfer gold-copper mine and its forward-looking development strategy. Day outlined the release of a 712,000-ounce gold and 23,000-tonne copper ore reserve for Telfer, achieved just five months post-acquisition. This comes on the heels of a 3.2 million ounce resource estimate, collectively taking the total resource base, including Havieron, beyond 10.0 million ounces. “This is really built on the back of Michael Thompson and his team,” Day said, noting the speed and scale of the update. He emphasized that the reserve confirms continuity at Telfer as Havieron ramps up, avoiding any production gap. Day also discussed the two-year dual-train production outlook through FY27 and emphasized the production and cost benefits expected once Havieron, a significantly higher-grade and lower-cost asset, is integrated. An updated feasibility study aims to expand Havieron from 2.8 to 4–4.5 million tonnes per annum, potentially via conveyor infrastructure to enhance economics and ESG performance. Looking ahead, Day pointed to opportunities to extend mine life, increase drilling, and develop the West Dome Underground. “The team is really humming right now,” he said. Visit Proactive’s YouTube channel for more videos like this. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #GreatlandGold #ShaunDay #TelferMine #Havieron #GoldMining #CopperMining #MiningUpdate #FeasibilityStudy #ASXMining #MineralResources #GoldInvesting #MiningDevelopment #ResourceUpdate

Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's transformation and its strategy moving into 2025. Tennyson explained that the company, formerly known as Graft Polymer, exited its industrial plastics business in 2024 to focus entirely on biotechnology, particularly mental health and addiction treatments. "These are segments which have large addressable markets, poor current standards of care and therefore significant unmet medical needs," he said. He outlined how the company raised £1.8 million in mid-2024 to support its new growth strategy, which includes partnerships, joint ventures, and acquisitions. A central part of this strategy is the pending acquisition of Awakn Life Sciences, a clinical-stage biotech company focused on alcohol use disorder (AUD) and PTSD. Solvonis is acquiring Awakn in an all-paper deal valued between £3 million and £5 million. Tennyson said this represented significant value, highlighting that similar assets could command substantially higher valuations. Awakn’s AWKN-001, targeting severe AUD, is in phase 3 trials in the UK and EU. AWKN-002, for the US market, has received FDA support for a faster 505(b)(2) development pathway, allowing the use of Johnson & Johnson’s SPRAVATO® data to accelerate progress. Tennyson said the top priority for 2025 is closing and integrating the acquisition and executing on the clinical programs. He emphasised plans to file for FDA approval of a phase 2B trial and to continue to work with Awakn's existing UK partners. Visit Proactive's YouTube channel for more updates like this. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #Solvonis #BiotechNews #MentalHealthTreatment #AddictionRecovery #PTSDResearch #AlcoholUseDisorder #PharmaInvesting #AwaknAcquisition #ClinicalTrials #HealthcareInnovation

Futura Medical PLC CEO James Barder takes Proactive's Stephen Gunnion through the company’s 2024 financial performance, market expansion and product pipeline. Futura reported a strong year in 2024, with CEO Barder highlighting revenue of £14 million and a maiden profit of £1.3 million—or £3.3 million excluding non-cash items. Barder noted that Eroxon is now sold in over 15 countries and is expected to reach over 20 by the end of 2025. “2024 was a very good year for us,” he said. Barder emphasised the company’s commitment to supporting commercial partners and building momentum behind its flagship product, Eroxon. He explained that markets seeing the most success were those effectively targeting men under 60 with mild to moderate erectile dysfunction—Eroxon’s most responsive user group. The conversation also touched on upcoming products, including Eroxon Intense, a variant delivering a stronger sensory experience, and SD4000, a topical treatment for female sexual dysfunction. Barder noted that 87% of women in clinical trials for SD4000 wished to continue use post-study—an encouraging sign. Looking ahead, Barder said the company will continue expanding its presence, drive forward its pipeline, and focus on areas it can control, despite share price frustrations. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell icon for updates. #FuturaMedical #Eroxon #EroxonIntense #SD4000 #ErectileDysfunction #FemaleHealth #PharmaNews #OTCProducts #HealthcareInnovation #BiotechUpdate

AltynGold PLC CEO Aidar Assaubayev talked with Proactive's Stephen Gunnionabout the company’s recent full-year results, operational developments, and growth plans for 2025. AltynGold, a low-cost gold producer operating in Kazakhstan, reported a transformational year with increased production capacity and significant infrastructure development at its flagship Sekisovskoye mine. Assaubayev highlighted a 50% increase in processing capacity to one million tonnes, the commissioning of a third production line, and a $50 million boost in EBITDA driven by cost control and operational efficiency. The company is now targeting 50,000 ounces of gold production in 2025—up 60% over two years. A central part of AltynGold’s growth strategy is the adjacent Teren-Sai license, where 54 core holes were drilled last year. Assaubayev said, “The data is currently being analysed to refine geological models and support the development of a more developed mine plan.” While noting that high gold prices are a positive, Assaubayev emphasised AltynGold’s resilience and long-term focus, stating the company is designed to perform across commodity cycles. On ESG performance, he said the company reported no major incidents in five years and continues to prioritise employee safety and community engagement. Looking forward, AltynGold remains focused on expanding its resource base, maintaining efficient operations, and exploring multi-asset opportunities to drive long-term value. Visit Proactive’s YouTube channel for more insightful interviews. Don’t forget to like, subscribe, and hit the notification bell for future updates. #AltynGold #GoldMining #KazakhstanMining #GoldProduction #MiningStocks #TerenSai #Sekisovskoye #GoldExploration #EBITDA #ResourceExpansion #GoldInvesting